Neuburgh Advisers’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Neuburgh Advisers’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-9,894	Closed	-$123K	–	918
2018 Q1	$123K	Sell	9,894 -29,750	-75%	-$362K	﹤0.01%	751
2017 Q4	$554K	Sell	39,644 -19,856	-33%	-$291K	0.02%	403
2017 Q3	$1M	Sell	59,500 -7,412	-11%	-$121K	0.04%	281
2017 Q2	$1.13M	Sell	66,912 -22,338	-25%	-$334K	0.04%	251
2017 Q1	$1.38M	Hold	89,250	–	–	0.05%	230
2016 Q4	$1.33M	Buy	+89,250	New	+$1.25M	0.06%	202

Other funds holding OXFD

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Neuburgh Advisers's OXFD Position: Q2 2018 in Review

Neuburgh Advisers sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q2 2018, closing a stake of 9,894 shares — an estimated $123K sold.

Neuburgh Advisers first reported a position in OXFD in Q4 2016 and held it in 6 quarters. The position peaked at $1.38M in Q1 2017. 77 funds tracked by Wall St. Rank hold OXFD as of Q2 2018.

Neuburgh Advisers reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q2 2018 after selling out during the quarter.
Neuburgh Advisers sold 9,894 Oxford Immunotec Global PLC Ordinary Shares shares in Q2 2018, an estimated $123K.
Neuburgh Advisers first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2016 and held it in 6 quarters.
Neuburgh Advisers's Oxford Immunotec Global PLC Ordinary Shares position peaked at $1.38M in Q1 2017.
77 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q2 2018.

Based on Neuburgh Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.